Toward empirical identification of a clinically meaningful indicator of treatment outcome: Features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes

Drug and Alcohol Dependence

Volumn 137, Issue 1, 2014, Pages 3-19

  Carroll, Kathleen M ^a   Kiluk, Brian D ^a   Nich, Charla ^a   DeVito, Elise E ^a   Decker, Suzanne ^a,b   LaPaglia, Donna ^a   Duffey, Dianne ^a   Babuscio, Theresa A ^a   Ball, Samuel A ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c New Haven Connecticut ^*  (United States)

Author keywords

Cocaine use disorders; Follow up studies; Randomized trials; Treatment outcome indicators

Indexed keywords

COCAINE; DISULFIRAM; METHADONE; OPIATE;

ABSTINENCE; ADDICTION SEVERITY INDEX; ADULT; ANXIETY; BEHAVIOR THERAPY; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DRUG USE; EFFECT SIZE; HUMAN; PRIORITY JOURNAL; REVIEW; SELF REPORT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; ANIMAL; CLINICAL TRIAL (TOPIC); COCAINE-RELATED DISORDERS; EMPIRICAL RESEARCH; EVALUATION STUDY; FOLLOW UP; HEALTH CARE QUALITY; STANDARDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; EMPIRICAL RESEARCH; FOLLOW-UP STUDIES; HUMANS; QUALITY INDICATORS, HEALTH CARE; TREATMENT OUTCOME;

EID: 84896074373     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.01.012     Document Type: Review

References (91)

1. Allen J.P. Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the national institute on alcohol abuse and alcoholism. Alcohol. Clin. Exp. Res. 2003, 27:1657-1660.
2. Anton R.E., Randall C.L. Measurement and choice of drinking outcome variables in the COMBINE Study. J. Stud. Alcohol 2005, Suppl.:104-109.
3. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R.M., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE Study. JAMA 2006, 2003-2017. for the COMBINE Study Research Group.
4. Babor T.F., Steinberg K., Anton R.F., Del Boca F.K. Talk is cheap: measuring drinking outcomes in clinical trials. J. Stud. Alcohol 2000, 61:55-63.
5. Carroll K.M., Ball S.A., Martino S., Nich C., Babuscio T., Gordon M.A., Portnoy G.A., Rounsaville B.J. Computer-assisted cognitive-behavioral therapy for addiction. A randomized clinical trial of 'CBT4CBT'. Am. J. Psychiatr. 2008, 165:881-888.
6. Carroll K.M., Ball S.A., Martino S., Nich C., Babuscio T.A., Rounsaville B.J. Enduring effects of a computer-assisted training program for cognitive-behavioral therapy: a six-month follow-up of CBT4CBT. Drug Alcohol Depend. 2009, 100:178-181.
7. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., Rounsaville B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychol. 2004, 61:264-272.
8. Carroll K.M., Nich C., Ball S.A., McCance E., Frankforter T.L., Rounsaville B.J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 2000, 95:1335-1349.
9. Carroll K.M., Nich C., Ball S.A., McCance E., Rounsavile B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93:713-727.
10. Carroll, K.M., Nich, C., Petry, N.M., Eagan, D., Shi, J., Ball, S.A., Herman, A., Sofuoglu, M., 2013. Disulfiram and contingency management to enhance CBT for cocaine dependence: effects on cocaine use and preliminary evidence for interactions with dopamine B-hydroxylase polymorphism, submitted for publication.
11. Carroll K.M., Nich C., Shi J.M., Eagan D., Ball S.A. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend. 2012, 126:224-231.
12. Carroll K.M., Rounsaville B.J., Nich C., Gordon L.T., Wirtz P.W., Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch. Gen. Psychol. 1994, 51:989-997.
13. Ciraulo D.A., Piechniczek-Buczek J., Iscan E.N. Outcome predictors in substance use disorders. Psychiatr. Clin. North Am. 2003, 26:381-409.
14. Cisler R.A., Kowalchulk R.K., Saunders S.M., Zweben A., Trinh H.Q. Applying clinical significance methodology to alcoholism treatment trials: determining recovery outcome status with individual- and population-based measures. Alcohol. Clin. Exp. Res. 2005, 29:1991-2000.
15. Cisler R.A., Zweben A. Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol. Clin. Exp. Res. 1999, 23:263-271.
16. Crits-Christoph P., Siqueland L., Blaine J.D., Frank A., Luborsky L., Onken L.S., Muenz L., Thase M.E., Weiss R.D., Gastfriend D.R., Woody G., Barber J.P., Butler S., Dale D., Salloum I., Bishop S., Najavits L., Lis J. Psychosocial treatments for cocaine dependence: results of the National Institute on Drug Abuse Collaborative Cocaine Study. Arch. Gen. Psychol. 1999, 56:495-502.
17. DeBusk R.F., Miller N.H., Superko H.R., Dennis C.A., Thomas R.J., Lew H.T., Berger W.E., Heller R.S., Rompf J., Gee D., Kraemer H.C., Bandura A., Ghandour G., Clark M., Shah R.V., Fisher L., Taylor C.B. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann. Intern. Med. 1994, 120:721-729.
18. Del Boca F.K., Noll J.A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000, 95:S347-S360.
19. Devos-Comby L., Lange J.E. "My drink is larger than yours"? A literature review of self-defined drink sizes and standard drinks. Curr. Drug Abuse Rev. 2008, 1:162-176.
20. Deyi B.A., Kosinski A.S., Snapinn S.M. Power considerations when a continuous outcome variable is dichotomized. J. Biopharm. Stat. 1998, 8:337-352.
21. Donovan D.M., Bigelow G.E., Brigham G.S., Carroll K.M., Cohen A.J., Gardin J.G., Hamilton J.A., Huestis M.A., Hughes J.R., Lindblad R., Marlatt G.A., Preston K.L., Selzer J.A., Somoza E.C., Wakim P.G., Wells E.A. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012, 107:694-708.
22. Assessment of Addictive Behaviors 2005, The Guilford Press, New York. 2nd ed. D.M. Donovan, G.A. Marlatt (Eds.).
23. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychol. 2008, 165:179-187.
24. Ehrman R.N., Robbins S.J., Cornish J.W. Results of a baseline urine test predict levels of cocaine use during treatment. Drug Alcohol Depend. 2001, 62:1-7.
25. Falk D., Wang X.Q., Liu L., Fertig J., Mattson M., Ryan M., Johnson B., Stout R., Litten R.Z. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol. Clin. Exp. Res. 2010, 34:2022-2034.
26. Finney J.W., Moyer A., Swearingen C.E. Outcome variables and their assessment in alcohol treatment studies: 1968-1998. Alcohol. Clin. Exp. Res. 2003, 27:1671-1679.
27. Gawin F.H., Kleber H.D., Byck R., Rounsaville B.J., Kosten T.R., Jatlow P.I., Morgan C. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychol. 1989, 46:117-121.
28. Hien D.A., Morgan-Lopez A.A., Campbell A.N., Saavedra L.M., Wu E., Cohen L., Ruglass L., Nunes E.V. Attendance and substance use outcomes for the Seeking Safety program: sometimes less is more. J. Consult. Clin. Psychol. 2012, 80:29-42.
29. Higgins S.T., Wong C.J., Badger G.J., Haug-Ogden D.E., Dantona R.L. Contingent reinforcement increases cocaine abstinence during outpatient treatment and one year follow-up. J. Consult. Clin. Psychol. 2000, 68:64-72.
30. Hser Y., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychol. 2001, 58:503-508.
31. Hser Y.I., Huang D., Brecht M.L., Li L., Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J. Addict. Dis. 2008, 27:13-21.
32. Hser Y.I., Stark M.E., Paredes A., Huang D., Anglin M.D., Rawson R.A. A 12-year follow-up of a treated cocaine-dependent sample. J. Subst. Abuse Treat. 2006, 30:219-226.
33. Huestis M.A., Cone E.J., Wong C.J., Umbricht A., Preston K.L. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J. Anal. Toxicol. 2000, 24:509-521.
34. Huestis M.A., Elsohly M., Nebro W., Barnes A., Gustafson R.A., Smith M.L. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther. Drug Monit. 2006, 28:540-544.
35. Huestis M.A., Mitchell J.M., Cone E.J. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J. Anal. Toxicol. 1995, 19:443-449.
36. Hughes J.R. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol. Addict. Behav. 2007, 21:127-137.
37. Hughes J.R., Carpenter M.J., Naud S. Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. Nicotine Tob. Res. 2010, 12:756-762.
38. Hughes J.R., Keely J.P., Niaura R.S., Ossip-Klein D.J., Richmond R.L., Swan G.E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 2003, 5:13-25.
39. Humphreys K., McLellan A.T. A policy-oriented review of strategies for improving the outcomes of services for substance use disorder patients. Addiction 2012, 106:2058-2066.
40. Jacobson N.S., Roberts L.J., Berns S.B., McGlinchey J.B. Methods for defining and determing the clinical significance of treatment effects: description, application and alternatives. J. Consult. Clin. Psychol. 1999, 67:300-307.
41. Jacobson N.S., Truax P.A. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 1991, 59:12-19.
42. Kazdin A.E., Bass D. Power to detect differences between alternative treatments in comparative psychotherapy outcome research. J. Consult. Clin. Psychol. 1989, 57:138-147.
43. Kendall P.C., Marrs-Garcia A., Nath S.R., Sheldrick R.C. Normative comparisions for the evaluation of clinical significance. J. Consult. Clin. Psychol. 1999, 67:285-299.
44. Korte J.E., Magruder K.M., Chiuzan C.C., Logan S.L., Killeen T., Bandyopadhyay D., Brady K.T. Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. Am. J. Drug Alcohol Abuse 2011, 37:358-366.
45. Kraemer H.C., Morgan G.A., Leech N.L., Gliner J.A., Vaske J.J., Harmon R.J. Measures of clinical significance. J. Am. Acad. Child Adolesc. Psychol. 2003, 42:1525-1549.
46. Kraemer H.C., Morgan G.A., Leech N.L., Gliner J.A., Vaske J.J., Harmon R.J. Measures of clinical significance. J. Am. Acad. Child Adolesc. Psychol. 2003, 42:1524-1529.
47. Lambert M.J., Bailey R.J. Measures of clinically significant change. APA Handbook of Research Methods in Psychology 2012, 147-160. American Psychological Association, Washington, DC. H. Cooper, P.M. Camic, D.L. Long, A.T. Panter, D. Rindskopf, K.J. Sher (Eds.).
48. Lavori P.W. Clinical trials in psychiatry: should protocol deviation censor patient data?. Neuropsychopharmocology 1992, 6:39-48.
49. Lavori P.W., Brown C.H., Duan N., Gibbons R.D., Greenhouse J. Missing data in longitudinal clinical trials. Part A: design and conceptual issues. Psychiatr. Ann. 2008, 38:784-792.
50. Mackinnon A. The use and reporting of multiple imputation in medical research - a review. J. Intern. Med. 2010, 268:586-593.
51. Mallinckrodt C.H., Watkin J.G., Molenberghs G., Carroll R.J. Choice of the primary analysis in longitudinal clinical trials. Pharm. Stat. 2004, 3:161-169.
52. Marsden J., Eastwood B., Bradbury C., Dale-Perera A., Farrell M., Hammond P., Knight J., Randhawa K., Wright C. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 2009, 374:1262-1270.
53. McCann D.J., Li S.H. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci. Ther. 2011, 18:414-418.
54. McKay J.R., Alterman A.I., Koppenhaver J.M., Mulvaney F.D., Bovasso G.B., Ward K. Continuous, categorical and time to event cocaine use outcome variables: degree of intercorrelation and sensitivity to treatment group differences. Drug Alcohol Depend. 2001, 62:19-31.
55. McLellan A.T. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 2002, 97:249-252.
56. McLellan A.T., Cacciola J.C., Alterman A.I., Rikoon S.H., Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. Am. J. Addict. 2006, 15:113-124.
57. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
58. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
59. Miller P.G., Miller W.R. What should we be aiming for in the treatment of addiction?. Addiction 2009, 104:685-686.
60. Miller W.R., Heather N., Hall W. Calculating standard drink units: international comparisons. Addiction 1991, 86:43-47.
61. Miller W.R., Manuel J.K. How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration. Drug Alcohol Rev. 2008, 27:524-528.
62. Morral A.R., Iguchi M.Y., Belding M.A., Lamb R.J. Natural classes of treatment response. J. Consult. Clin. Psychol. 1997, 65:673-685.
63. National Institute on Drug Abuse Principles of Drug Addiction Treatment: A Research Based Guide 2007, NIDA, Bethesda, MD.
64. Nich C., Carroll K.M. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend. 2002, 68:121-130.
65. Peters E.N., Nich C., Carroll K.M. Primary outcomes in two randomized controlled trials of treatments for cannabis use disorders. Drug Alcohol Depend. 2011, 118:408-416.
66. Preston K.L., Huestis M.A., Wong C.J., Umbricht A., Goldberger B.A., Cone E.J. Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing. J. Anal. Toxicol. 1999, 23:313-322.
67. Preston K.L., Silverman K., Schuster C.R., Cone E.J. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction 1997, 92:717-727.
68. Robinson S.M., Sobell L.C., Sobell M.B., Leo G.I. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psych Addict. Behav. 2014, (in press).
69. Schuler M.S., Lechner W.V., Carter R.E., Malcolm R. Temporal and gender trends in concordance of urine drug screens and self-reported use in cocaine treatment studies. J. Addict. Med. 2009, 3:211-217.
70. Schwartz R.H. Urine testing in the detection of drugs of abuse. Arch. Int. Med. 1988, 148:2407-2412.
71. Schwilke E.W., Gulberg R.G., Darwin W.D., Chiang C.N., Cadet J.L., Gorelick D.A., Pope H.G., Huestis M. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic daily cannabis users. Addiction 2010, 106:499-506.
72. Siddique J., Brown C.H., Hedeker D., Duan N., Gibbons R.D., Miranda J., Lavori P.W. Missing data in longitudinal trials. Part B: analytic issues. Psychiatr. Ann. 2008, 38:793-801.
73. Simpson D.D., Joe G.W., Brown B.S. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 1997, 11:294-307.
74. Simpson D.D., Joe G.W., Fletcher B.W., Hubbard R.L., Anglin M.D. A national evaluation of treatment outcomes for cocaine dependence. Arch. Gen. Psychol. 1999, 56:507-514.
75. Snapinn S.M., Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007, 8:31.
76. Sobell L.C., Sobell M.B. Timeline followback: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption: Psychosocial and Biological Methods 1992, 41-72. Humana Press, New Jersey. R.Z. Litten, J. Allen (Eds.).
77. Sobell L.C., Sobell M.B., Connors G.J., Agrawal S. Assessing drinking outcomes in alcohol treatment efficacy studies: selecting a yardstick of success. Alcohol. Clin. Exp. Res. 2003, 27:1661-1666.
78. Somoza E., Somoza P., Lewis D., Li S.H., Winhusen T., Chiang N., Vocci F., Horn P., Elkashef A. The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study day. Drug Alcohol Depend. 2008, 93:132-140.
79. Spratt M., Carpenter J., Sterne J.A., Carlin J.B., Heron J., Henderson J., Tilling K. Strategies for multiple imputation in longitudinal studies. Am. J. Epidemiol. 2010, 172:478-487.
80. Tiffany S.T., Carter B.L., Singleton E.G. Challenges in the manipulation, assessment and interpretation of craving relevant variables. Addiction 2000, 95:S177-S187.
81. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction 2012, 107:709-718.
82. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R. Other outcomes in treatments for substance-use disorders: a call for action. Addiction 2012, 107:725-726.
83. Tiffany S.T., Wray J.M. The clinical significance of drug craving. Ann. N. Y. Acad. Sci. 2012, 1248:1-17.
84. Velicer W.F., Prochaska J.O. A comparison of four self-report smoking cessation outcome measures. Addict. Behav. 2004, 29:51-60.
85. Vocci F.J. Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda. Exp. Clin. Psychopharmocol. 2008, 16:484-497.
86. Volkow N.D. What do we know about drug addiction?. Am. J. Psychol. 2005, 162:1401-1402.
87. Walker R. Retention in treatment - indicator or illusion: an essay. Subst. Use Misuse 2009, 44:18-27.
88. Wells E.A., Saxon A.J., Calsyn D.A., Jackson T.R., Donovan D.M. Study results from the Clinical Trials Network's first 10 years: where do they lead?. J. Subst. Abuse Treat. 2010, 38(Suppl. 1):S14-S30.
89. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005, 100:299-303.
90. Winchell C., Rappaport B.A., Roca R., Rosebraugh C.J. Reanalysis of methamphetamine dependence treatment trial. CNS Neurosci. Ther. 2012, 18:367-368.
91. Witkiewitz K. "Success" following alcohol treatment: moving beyond abstinence. Alcohol. Clin. Exp. Res. 2013, 37(S1):E9-E13.